Journal of Southern Medical University ›› 2026, Vol. 46 ›› Issue (10): 2494-2508.doi: 10.12122/j.issn.1673-4254.2026.10.18
Dunlin HU1(
), Hui GUO1, Xiaojuan WANG1, Yu LI1, Chi ZHANG1, Xiaohu CHEN1, XiaoLi NIE1,2(
)
Received:2026-03-25
Online:2026-10-20
Published:2026-10-26
Contact:
XiaoLi NIE
E-mail:hudunlin1218@163.com;nxl117@163.com
Supported by:Dunlin HU, Hui GUO, Xiaojuan WANG, Yu LI, Chi ZHANG, Xiaohu CHEN, XiaoLi NIE. LGALS3 is an efferocytosis-related biomarker and potential traditional Chinese medicine therapeutic target for diabetic kidney disease complicated with heart failure[J]. Journal of Southern Medical University, 2026, 46(10): 2494-2508.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.j-smu.com/EN/10.12122/j.issn.1673-4254.2026.10.18
| Gene | Candidate TCMs |
|---|---|
| S100A9 | Albizia julibrissin, Caragana sinensis (whole herb, root, flower), Isatis tinctoria leaf, Baphicacanthus cusia root, Smilax glabra, Gentiana scabra, Abelmoschus manihot, Alisma plantago-aquatica, Momordica charantia, Evodia rutaecarpa, Rheum palmatum, Catharsius molossus |
| FPR2 | Rhododendron dauricum, Sparganium stoloniferum, Sargentodoxa cuneata, Patrinia villosa, Lindera aggregata, Ganoderma applanatum, Scolopendra subspinipes, Corydalis yanhusuo, Cyperus rotundus, Paeonia lactiflora, Glycyrrhiza uralensis, Angelica sinensis |
| TREM1 | Abelmoschus manihot, Ligusticum spp. (including L. chuanxiong, L. sinense), Rehmannia glutinosa (fresh & dried), Prunus persica (seed, immature fruit, twig), Angelica sinensis |
| LGALS3 | Stellaria dichotoma, Smilax china, Notopterygium incisum, Gynostemma pentaphyllum, Panax japonicus (whole herb & leaf), Camellia japonica (root & flower), Rehmannia glutinosa (fresh & dried), Arca subcrenata, Crataegus pinnatifida |
| CD86 | Cyathula officinalis, Plantago asiatica (herb & seed), Patrinia villosa, Ganoderma lucidum, Poria cocos, Polygonum cuspidatum, Arisaema erubescens, Pinellia pedatisecta, Achyranthes bidentata, Hericium erinaceus, Belamcanda chinensis, Polyporus umbellatus, Nidus vespae, Lycium barbarum (cultivated & wild fruit), Cordyceps sinensis, Curcuma longispica*, Moschus (natural & artificial), Astragalus membranaceus, Sanguisorba officinalis, Atractylodes macrocephala, Sargentodoxa cuneata, Platycodon grandiflorus, Panax ginseng (whole herb, leaf, flower, dew), Cistanche deserticola, Uncaria rhynchophylla, Rosa laevigata (root & fruit), Caesalpinia sappan, Laminaria japonica, Forsythia suspensa, Codonopsis spp. (including C. pilosula, C. lanceolata), Scutellaria baicalensis, Panax notoginseng (whole herb, leaf, flower), Schizonepeta tenuifolia, Arca subcrenata, Dryopteris crassirhizoma, Lindera aggregata, Manis pentadactyla, Schisandra chinensis, Collocalia esculenta nest |
| CXCL1 | Albizia julibrissin, Sanguisorba officinalis, Lycoris radiata, Manis pentadactyla, Scutellaria baicalensis, Artemisia capillaris, Siraitia grosvenorii, Hibiscus mutabilis flower, Chrysanthemum indicum, Oroxylum indicum, Hedyotis diffusa, Angelica dahurica |
| FCGR2A | Polygonum multiflorum, Codonopsis pilosula, Naja naja |
| IL1R2 | Artemisia argyi fruit, Artemisia (Baihuahao), Perilla frutescens (seed, fried seed, stalk), Camellia sinensis, Bufo bufo (Fried), Eugenia caryophyllata (root, bark, leaf, twig, oil, dew), Pimenta dioica, Psidium guajava leaf, Achyranthes aspera, Cinnamomum cassia bark, Piper betle leaf, Prunus armeniaca seed (Bitter), Sonchus arvensis, Amomum villosum, Mosla chinensis, Dianthus chinensis, Origanum vulgare, Cinnamomum camphora, Aconitum coreanum, Laurus nobilis seed, Myrrha (Processed) |
| CD1C | Areca catechu (seed, processed seed, pericarp), Codonopsis lanceolata, Santalum album, Thevetia peruviana (leaf & seed), Mentha spicata, Tremella fuciformis, Achyranthes bidentata, Angelica dahurica, Ligusticum chuanxiong |
| FLT3 | Dolichos lablab (whole herb, flower, coat), Atractylodes macrocephala, Lonicera japonica caulis, Rehmannia glutinosa (fresh & dried), Coriandrum sativum (whole herb & fruit), Lonicera japonica flower, Camellia sinensis root, Astragalus membranaceus |
| SOCS3 | Omphalia lapidescens, Mahonia fortunei (whole herb, leaf, wood), Alisma plantago-aquatica, Curcuma aromatica, Curcuma zedoaria, Lindera aggregata, Peucedanum praeruptorum, Tremella fuciformis, Rosa chinensis flower, Cuscuta chinensis, Euphorbia kansui, Tribulus terrestris, Limonite, Isinglass, Scutellaria baicalensis, Dendrobium nobile, Artemisia capillaris, Artemisia anomala, Polygala tenuifolia, Atractylodes lancea, Perilla frutescens (whole herb, seed, stalk, tops), Momordica charantia, Isatis tinctoria leaf |
| S100A8 | Albizia julibrissin, Smilax glabra, Abelmoschus manihot, Catharsius molossus, Bubalus bubalis horn, Portulaca oleracea, Cervus nippon antler (velvet & osseous), Rheum palmatum, Ganoderma lucidum |
| MSR1 | Gentiana lutea, Elephantopus scaber, Sophora alopecuroides, Arctium lappa (root & seed), Atractylodes macrocephala, Laminaria japonica, Curcuma aromatica, Curcuma longa, Perilla frutescens |
Tab.1 Predicted results for Chinese medicines
| Gene | Candidate TCMs |
|---|---|
| S100A9 | Albizia julibrissin, Caragana sinensis (whole herb, root, flower), Isatis tinctoria leaf, Baphicacanthus cusia root, Smilax glabra, Gentiana scabra, Abelmoschus manihot, Alisma plantago-aquatica, Momordica charantia, Evodia rutaecarpa, Rheum palmatum, Catharsius molossus |
| FPR2 | Rhododendron dauricum, Sparganium stoloniferum, Sargentodoxa cuneata, Patrinia villosa, Lindera aggregata, Ganoderma applanatum, Scolopendra subspinipes, Corydalis yanhusuo, Cyperus rotundus, Paeonia lactiflora, Glycyrrhiza uralensis, Angelica sinensis |
| TREM1 | Abelmoschus manihot, Ligusticum spp. (including L. chuanxiong, L. sinense), Rehmannia glutinosa (fresh & dried), Prunus persica (seed, immature fruit, twig), Angelica sinensis |
| LGALS3 | Stellaria dichotoma, Smilax china, Notopterygium incisum, Gynostemma pentaphyllum, Panax japonicus (whole herb & leaf), Camellia japonica (root & flower), Rehmannia glutinosa (fresh & dried), Arca subcrenata, Crataegus pinnatifida |
| CD86 | Cyathula officinalis, Plantago asiatica (herb & seed), Patrinia villosa, Ganoderma lucidum, Poria cocos, Polygonum cuspidatum, Arisaema erubescens, Pinellia pedatisecta, Achyranthes bidentata, Hericium erinaceus, Belamcanda chinensis, Polyporus umbellatus, Nidus vespae, Lycium barbarum (cultivated & wild fruit), Cordyceps sinensis, Curcuma longispica*, Moschus (natural & artificial), Astragalus membranaceus, Sanguisorba officinalis, Atractylodes macrocephala, Sargentodoxa cuneata, Platycodon grandiflorus, Panax ginseng (whole herb, leaf, flower, dew), Cistanche deserticola, Uncaria rhynchophylla, Rosa laevigata (root & fruit), Caesalpinia sappan, Laminaria japonica, Forsythia suspensa, Codonopsis spp. (including C. pilosula, C. lanceolata), Scutellaria baicalensis, Panax notoginseng (whole herb, leaf, flower), Schizonepeta tenuifolia, Arca subcrenata, Dryopteris crassirhizoma, Lindera aggregata, Manis pentadactyla, Schisandra chinensis, Collocalia esculenta nest |
| CXCL1 | Albizia julibrissin, Sanguisorba officinalis, Lycoris radiata, Manis pentadactyla, Scutellaria baicalensis, Artemisia capillaris, Siraitia grosvenorii, Hibiscus mutabilis flower, Chrysanthemum indicum, Oroxylum indicum, Hedyotis diffusa, Angelica dahurica |
| FCGR2A | Polygonum multiflorum, Codonopsis pilosula, Naja naja |
| IL1R2 | Artemisia argyi fruit, Artemisia (Baihuahao), Perilla frutescens (seed, fried seed, stalk), Camellia sinensis, Bufo bufo (Fried), Eugenia caryophyllata (root, bark, leaf, twig, oil, dew), Pimenta dioica, Psidium guajava leaf, Achyranthes aspera, Cinnamomum cassia bark, Piper betle leaf, Prunus armeniaca seed (Bitter), Sonchus arvensis, Amomum villosum, Mosla chinensis, Dianthus chinensis, Origanum vulgare, Cinnamomum camphora, Aconitum coreanum, Laurus nobilis seed, Myrrha (Processed) |
| CD1C | Areca catechu (seed, processed seed, pericarp), Codonopsis lanceolata, Santalum album, Thevetia peruviana (leaf & seed), Mentha spicata, Tremella fuciformis, Achyranthes bidentata, Angelica dahurica, Ligusticum chuanxiong |
| FLT3 | Dolichos lablab (whole herb, flower, coat), Atractylodes macrocephala, Lonicera japonica caulis, Rehmannia glutinosa (fresh & dried), Coriandrum sativum (whole herb & fruit), Lonicera japonica flower, Camellia sinensis root, Astragalus membranaceus |
| SOCS3 | Omphalia lapidescens, Mahonia fortunei (whole herb, leaf, wood), Alisma plantago-aquatica, Curcuma aromatica, Curcuma zedoaria, Lindera aggregata, Peucedanum praeruptorum, Tremella fuciformis, Rosa chinensis flower, Cuscuta chinensis, Euphorbia kansui, Tribulus terrestris, Limonite, Isinglass, Scutellaria baicalensis, Dendrobium nobile, Artemisia capillaris, Artemisia anomala, Polygala tenuifolia, Atractylodes lancea, Perilla frutescens (whole herb, seed, stalk, tops), Momordica charantia, Isatis tinctoria leaf |
| S100A8 | Albizia julibrissin, Smilax glabra, Abelmoschus manihot, Catharsius molossus, Bubalus bubalis horn, Portulaca oleracea, Cervus nippon antler (velvet & osseous), Rheum palmatum, Ganoderma lucidum |
| MSR1 | Gentiana lutea, Elephantopus scaber, Sophora alopecuroides, Arctium lappa (root & seed), Atractylodes macrocephala, Laminaria japonica, Curcuma aromatica, Curcuma longa, Perilla frutescens |
| TCM | Frequency | Targets |
|---|---|---|
| Scutellaria baicalensis | 3 | CD86、CXCL1、SOCS3 |
| Rehmannia glutinosa (Fresh) | 3 | TREM1、LGALS3、FLT3 |
| Rehmannia glutinosa (Dried) | 3 | TREM1、FLT3、LGALS3 |
| Atractylodes macrocephala | 3 | CD86、FLT3、MSR1 |
| Albizia julibrissin | 3 | CXCL1、S100A8、S100A9 |
| Abelmoschus manihot | 3 | S100A9、TREM1、S100A8 |
| Lindera aggregata | 3 | SOCS3、FPR2、CD86 |
| Ligusticum chuanxiong | 2 | TREM1、CD1C、 |
| Astragalus membranaceus | 2 | CD86、FLT3 |
| Gentiana scabra | 2 | S100A9、MSR1 |
| Achyranthes bidentata | 2 | CD86、CD1C |
| Rheum palmatum | 2 | S100A8、S100A9 |
| Alisma plantago-aquatica | 2 | S100A9、SOCS3 |
| Curcuma aromatica | 2 | SOCS3、MSR1 |
| Curcuma longa | 2 | MSR1、CD86 |
Tab.2 Gene effect frequency of various herbal materials
| TCM | Frequency | Targets |
|---|---|---|
| Scutellaria baicalensis | 3 | CD86、CXCL1、SOCS3 |
| Rehmannia glutinosa (Fresh) | 3 | TREM1、LGALS3、FLT3 |
| Rehmannia glutinosa (Dried) | 3 | TREM1、FLT3、LGALS3 |
| Atractylodes macrocephala | 3 | CD86、FLT3、MSR1 |
| Albizia julibrissin | 3 | CXCL1、S100A8、S100A9 |
| Abelmoschus manihot | 3 | S100A9、TREM1、S100A8 |
| Lindera aggregata | 3 | SOCS3、FPR2、CD86 |
| Ligusticum chuanxiong | 2 | TREM1、CD1C、 |
| Astragalus membranaceus | 2 | CD86、FLT3 |
| Gentiana scabra | 2 | S100A9、MSR1 |
| Achyranthes bidentata | 2 | CD86、CD1C |
| Rheum palmatum | 2 | S100A8、S100A9 |
| Alisma plantago-aquatica | 2 | S100A9、SOCS3 |
| Curcuma aromatica | 2 | SOCS3、MSR1 |
| Curcuma longa | 2 | MSR1、CD86 |
| TCM | Degree | Betweenness Centrality | Closeness Centrality |
|---|---|---|---|
| Scutellaria baicalensis | 29 | 0.543300408 | 0.276162791 |
| Astragalus membranaceus | 14 | 0.329422848 | 0.238693467 |
| Rehmannia glutinosa (Fresh) | 14 | 0.283225084 | 0.201271186 |
| Curcuma aromatica | 9 | 0.160821599 | 0.213963964 |
| Achyranthes bidentata | 8 | 0.307002216 | 0.247395833 |
Tab.3 Topological parameters of key traditional Chinese medicines
| TCM | Degree | Betweenness Centrality | Closeness Centrality |
|---|---|---|---|
| Scutellaria baicalensis | 29 | 0.543300408 | 0.276162791 |
| Astragalus membranaceus | 14 | 0.329422848 | 0.238693467 |
| Rehmannia glutinosa (Fresh) | 14 | 0.283225084 | 0.201271186 |
| Curcuma aromatica | 9 | 0.160821599 | 0.213963964 |
| Achyranthes bidentata | 8 | 0.307002216 | 0.247395833 |
| TCM | Ingredient | Mol ID | Mw | AlogP (MiLogP) | Hdon | Hacc | OB (%) | DL | Lipinski (Y/N) | |
|---|---|---|---|---|---|---|---|---|---|---|
| Scutellaria baicalensis | coptisine | MOL 001458 | 320.34 | 3.25 | 0 | 4 | 30.67 | 0.86 | Y | |
| baicalein | MOL 002714 | 270.25 | 2.33 | 3 | 5 | 33.52 | 0.21 | Y | ||
| wogonin | MOL 000173 | 284.2 | 2.59 | 2 | 5 | 30.68 | 0.23 | Y | ||
| Astragalus membranaceus | quercetin | MOL 000098 | 302.25 | 1.5 | 5 | 7 | 46.43 | 0.28 | Y | |
| kaempferol | MOL 000422 | 286.25 | 1.77 | 4 | 6 | 41.88 | 0.24 | Y | ||
| Curcuma aromatica | (E)-5-Hydroxy-7-(4-hydroxyphenyl) -1-phenyl-1-heptene | MOL 004263 | 282.41 | 4.59 | 2 | 2 | 46.9 | 0.19 | Y | |
| Achyranthes bidentata | epiberberine | MOL 002897 | 336.39 | 3.45 | 0 | 4 | 43.09 | 0.78 | Y | |
| Rehmannia glutinosa (Fresh) | salidroside | HBIN 042854 | 300.3 | 3.2 | 3 | 5 | N/A | N/A | Y | |
| diincarvilone A | HBIN 024020 | 480.64 | -0.6 | 5 | 7 | N/A | N/A | Y | ||
Tab.4 Key ingredients in traditional Chinese medicines
| TCM | Ingredient | Mol ID | Mw | AlogP (MiLogP) | Hdon | Hacc | OB (%) | DL | Lipinski (Y/N) | |
|---|---|---|---|---|---|---|---|---|---|---|
| Scutellaria baicalensis | coptisine | MOL 001458 | 320.34 | 3.25 | 0 | 4 | 30.67 | 0.86 | Y | |
| baicalein | MOL 002714 | 270.25 | 2.33 | 3 | 5 | 33.52 | 0.21 | Y | ||
| wogonin | MOL 000173 | 284.2 | 2.59 | 2 | 5 | 30.68 | 0.23 | Y | ||
| Astragalus membranaceus | quercetin | MOL 000098 | 302.25 | 1.5 | 5 | 7 | 46.43 | 0.28 | Y | |
| kaempferol | MOL 000422 | 286.25 | 1.77 | 4 | 6 | 41.88 | 0.24 | Y | ||
| Curcuma aromatica | (E)-5-Hydroxy-7-(4-hydroxyphenyl) -1-phenyl-1-heptene | MOL 004263 | 282.41 | 4.59 | 2 | 2 | 46.9 | 0.19 | Y | |
| Achyranthes bidentata | epiberberine | MOL 002897 | 336.39 | 3.45 | 0 | 4 | 43.09 | 0.78 | Y | |
| Rehmannia glutinosa (Fresh) | salidroside | HBIN 042854 | 300.3 | 3.2 | 3 | 5 | N/A | N/A | Y | |
| diincarvilone A | HBIN 024020 | 480.64 | -0.6 | 5 | 7 | N/A | N/A | Y | ||
| Protein | Protein structure | Molecular | Affinity (kcal/mol) |
|---|---|---|---|
| LGALS3 | ![]() | quercetin | 6.8 |
| kaempferol | 6.1 |
Tab.5 Vina scores for docking simulations
| Protein | Protein structure | Molecular | Affinity (kcal/mol) |
|---|---|---|---|
| LGALS3 | ![]() | quercetin | 6.8 |
| kaempferol | 6.1 |
| Clinical Indicators | HC (n=15) | DKD (n=15) | CHF (n=15) | DKD+CHF (n=15) | (F/H/χ2) | P |
|---|---|---|---|---|---|---|
| Male [male, n (%)] | 7 (46.7%) | 7 (46.7%) | 7 (46.7%) | 8 (53.3%) | χ2=0.20 | 0.978 |
| Age (Mean±SD) | 66.40±11.30 | 66.67±6.59 | 65.73±13.66 | 68.80±7.76 | F=0.25 | 0.859 |
| BMI (Mean±SD) | 22.98±2.04 | 24.33±3.49 | 22.69±3.56 | 24.79±3.70 | F=1.47 | 0.232 |
| Cr (Median [IQR]) | 68.00 [62.50, 77.50] | 478.00 [271.50, 503.50]** | 71.00 [63.50, 84.50]## | 293.00 [201.00, 576.50]**&& | H=36.47 | <0.001 |
| BUN (Median [IQR]) | 5.06 [4.58, 5.80] | 24.10 [16.30, 29.30]** | 6.20 [5.65, 7.50]## | 17.10 [9.90, 23.30]**&& | H=40.46 | <0.001 |
| UA (Median [IQR]) | 324.00 [280.00, 364.00] | 416.00 [326.00, 475.00] | 362.00 [280.00, 483.50] | 406.00 [272.50, 504.00] | H=5.12 | 0.163 |
| eGFR (Mean±SD) | 87.60±7.64 | 14.87±10.50** | 84.20±13.92## | 25.67±29.51**&& | F=70.88 | <0.001 |
| LVEF (Mean±SD) | 64.40±4.67 | 65.07±3.67 | 40.53±10.76**## | 52.80±9.99**##&& | F=32.02 | <0.001 |
| LVEDD (Mean±SD) | 43.80±3.55 | 44.93±4.18 | 58.00±10.06**## | 49.53±5.14&& | F=15.84 | <0.001 |
| HbA1c (Mean±SD) | 5.59±0.28 | 7.51±1.49** | 5.64±0.40## | 7.95±2.00**&& | F=14.05 | <0.001 |
NT_proBNP (Median [IQR]) | 59.37 [28.41, 162.60] | 382.00 [283.50, 744.65]** | 4480.00 [2989.00, 17888.50]**## | 3120.00 [1432.50, 24311.00]**## | H=44.46 | <0.001 |
| hs_cTnT (Median [IQR]) | 7.20 [6.08, 9.27] | 25.10 [17.45, 31.20]** | 43.68 [31.50, 74.00]**# | 79.80 [47.15, 141.06]**# | H=37.11 | <0.001 |
| TC (Mean±SD) | 4.46±0.74 | 3.92±1.03 | 4.15±0.71 | 3.90±0.87 | F=1.42 | 0.247 |
| TG (Median [IQR]) | 1.26 [0.99, 1.60] | 1.73 [1.50, 2.33]* | 1.20 [0.86, 1.57]# | 1.85 [1.51, 2.13]*& | H=17.15 | <0.001 |
| LDL_C (Mean±SD) | 2.77±0.63 | 2.13±0.56* | 2.14±0.54* | 2.26±0.63 | F=3.93 | 0.013 |
Tab.6 Comparison of baseline characteristics of clinical subjects in each group
| Clinical Indicators | HC (n=15) | DKD (n=15) | CHF (n=15) | DKD+CHF (n=15) | (F/H/χ2) | P |
|---|---|---|---|---|---|---|
| Male [male, n (%)] | 7 (46.7%) | 7 (46.7%) | 7 (46.7%) | 8 (53.3%) | χ2=0.20 | 0.978 |
| Age (Mean±SD) | 66.40±11.30 | 66.67±6.59 | 65.73±13.66 | 68.80±7.76 | F=0.25 | 0.859 |
| BMI (Mean±SD) | 22.98±2.04 | 24.33±3.49 | 22.69±3.56 | 24.79±3.70 | F=1.47 | 0.232 |
| Cr (Median [IQR]) | 68.00 [62.50, 77.50] | 478.00 [271.50, 503.50]** | 71.00 [63.50, 84.50]## | 293.00 [201.00, 576.50]**&& | H=36.47 | <0.001 |
| BUN (Median [IQR]) | 5.06 [4.58, 5.80] | 24.10 [16.30, 29.30]** | 6.20 [5.65, 7.50]## | 17.10 [9.90, 23.30]**&& | H=40.46 | <0.001 |
| UA (Median [IQR]) | 324.00 [280.00, 364.00] | 416.00 [326.00, 475.00] | 362.00 [280.00, 483.50] | 406.00 [272.50, 504.00] | H=5.12 | 0.163 |
| eGFR (Mean±SD) | 87.60±7.64 | 14.87±10.50** | 84.20±13.92## | 25.67±29.51**&& | F=70.88 | <0.001 |
| LVEF (Mean±SD) | 64.40±4.67 | 65.07±3.67 | 40.53±10.76**## | 52.80±9.99**##&& | F=32.02 | <0.001 |
| LVEDD (Mean±SD) | 43.80±3.55 | 44.93±4.18 | 58.00±10.06**## | 49.53±5.14&& | F=15.84 | <0.001 |
| HbA1c (Mean±SD) | 5.59±0.28 | 7.51±1.49** | 5.64±0.40## | 7.95±2.00**&& | F=14.05 | <0.001 |
NT_proBNP (Median [IQR]) | 59.37 [28.41, 162.60] | 382.00 [283.50, 744.65]** | 4480.00 [2989.00, 17888.50]**## | 3120.00 [1432.50, 24311.00]**## | H=44.46 | <0.001 |
| hs_cTnT (Median [IQR]) | 7.20 [6.08, 9.27] | 25.10 [17.45, 31.20]** | 43.68 [31.50, 74.00]**# | 79.80 [47.15, 141.06]**# | H=37.11 | <0.001 |
| TC (Mean±SD) | 4.46±0.74 | 3.92±1.03 | 4.15±0.71 | 3.90±0.87 | F=1.42 | 0.247 |
| TG (Median [IQR]) | 1.26 [0.99, 1.60] | 1.73 [1.50, 2.33]* | 1.20 [0.86, 1.57]# | 1.85 [1.51, 2.13]*& | H=17.15 | <0.001 |
| LDL_C (Mean±SD) | 2.77±0.63 | 2.13±0.56* | 2.14±0.54* | 2.26±0.63 | F=3.93 | 0.013 |
Fig.2 Identification of DEGs in DKD and CHF. Fig.2 Identification of the differentially expressed genes (DEGs) in diabetic kidney disease (DKD) and chronic heart failure (CHF). A: Volcano plot of DEGs in DKD (red represents up-regulated and green represents down-regulated genes). B: Heatmap of DEGs in DKD. C: Volcano plot of DEGs in CHF. D: Heatmap of DEGs in CHF. E: Venn diagram illustrating the intersection of DEGs between DKD and CHF, identifying a total of 22 shared comorbidity DEGs.
Fig.3 Screening of key co-expression modules via weighted gene co expression network analysis (WGCNA). A, B: Network topology analysis of the DKD (A) and CHF (B) datasets. C, D: Gene clustering dendrograms and module cutting for DKD (C) and CHF (D). E, F: Heatmaps of module-trait relationships for DKD (E) and CHF (F). G: Shared module genes of WGCNA.
Fig.4 Functional enrichment analysis of the common core genes. A, B: Complete PPI networks of core targets constructed using the STRING database (A: Full network; B: Key modules). C: Bubble plot of GO enrichment analysis. D: Sankey diagram of KEGG pathway enrichment analysis. In C and D, the size of the dots represents the number of genes, and the color indicates the significance of the P-value.
Fig.5 PPI network construction and screening of hub genes. A: PPI network of the 50 comorbidity core genes constructed based on the STRING database. B: A key module comprising 13 hub genes identified through clustering using the MCODE plugin in Cytoscape.
Fig.6 Pharmacological properties of potential TCMs and the "Gene-Herb-Ingredient" network. A-D: Statistical distributions of the pharmacological properties of the predicted TCMs (A: Efficacy categories; B: Meridian tropisms; C: Natures; D: Flavors). E: Venn diagram of the intersecting targets between the diseases and the predicted TCMs. F: "Core comorbidity gene-TCM-active ingredient" regulatory network (larger nodes indicate higher Degree values).
Fig.7 Validation of hub gene expression and molecular docking simulation. A, B: Expression levels of the core genes in the validation datasets (A: DKD dataset GSE30122; B: CHF dataset GSE5406). C: Molecular docking model of the key active ingredient quercetin with the core target LGALS3 (binding energy: -6.8 kcal/mol). (*P<0.05).
Fig.8 Comparison of serum LGALS3 levels among the 4 groups (Mean±SD, n=15). Control: Healthy control group; DKD: Diabetic kidney disease group; CHF: Chronic heart failure group; DKD+CHF: DKD combined with CHF group. ***P<0.001, ****P<0.0001.
| Variables | β | SE | 95% CI | t | P |
|---|---|---|---|---|---|
| (Intercept) | 31.88 | 28.48 | -25.32-89.09 | 1.12 | 0.268 |
| Group DKD (vs HC) | -9.84 | 13.1 | -36.17-16.49 | -0.75 | 0.456 |
| Group CHF (vs HC) | -7.19 | 11.65 | -30.61-16.23 | -0.62 | 0.54 |
| Group DKD+CHF (vs HC) | 51.2 | 13.29 | 24.50-77.91 | 3.85 | <0.001 |
| Age | -0.04 | 0.26 | -0.57-0.49 | -0.15 | 0.88 |
| Gender(Male) | -7.37 | 4.96 | -17.35-2.60 | -1.49 | 0.144 |
| eGFR | -0.26 | 0.16 | -0.58-0.05 | -1.68 | 0.099 |
| logNTproBNP | 5.17 | 2.18 | 0.78-9.56 | 2.37 | 0.022 |
| HbA1c | -0.54 | 2.01 | -4.58-3.51 | -0.27 | 0.79 |
Tab.7 Multivariate linear regression analysis of factors affecting serum LGALS3
| Variables | β | SE | 95% CI | t | P |
|---|---|---|---|---|---|
| (Intercept) | 31.88 | 28.48 | -25.32-89.09 | 1.12 | 0.268 |
| Group DKD (vs HC) | -9.84 | 13.1 | -36.17-16.49 | -0.75 | 0.456 |
| Group CHF (vs HC) | -7.19 | 11.65 | -30.61-16.23 | -0.62 | 0.54 |
| Group DKD+CHF (vs HC) | 51.2 | 13.29 | 24.50-77.91 | 3.85 | <0.001 |
| Age | -0.04 | 0.26 | -0.57-0.49 | -0.15 | 0.88 |
| Gender(Male) | -7.37 | 4.96 | -17.35-2.60 | -1.49 | 0.144 |
| eGFR | -0.26 | 0.16 | -0.58-0.05 | -1.68 | 0.099 |
| logNTproBNP | 5.17 | 2.18 | 0.78-9.56 | 2.37 | 0.022 |
| HbA1c | -0.54 | 2.01 | -4.58-3.51 | -0.27 | 0.79 |
| [1] | Wang LY, Li LX, Liu JX, et al. Associated factors and principal pathophysiological mechanisms of type 2 diabetes mellitus[J]. Front Endocrinol, 2025, 16: 1499565. doi:10.3389/fendo.2025.1499565 |
| [2] | Parmar S, Lopez T, Shah R, et al. Risk of hospital admissions and death in patients with heart failure and chronic kidney disease: findings from a novel multidisciplinary clinic[J]. Cardiorenal Med, 2025, 15(1): 249-60. doi:10.1159/000541806 |
| [3] | Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities[J]. Clin J Am Soc Nephrol, 2017, 12(12): 2032-45. doi:10.2215/cjn.11491116 |
| [4] | Schefold JC, Filippatos G, Hasenfuss G, et al. Heart failure and kidney dysfunction: epidemiology, mechanisms and management[J]. Nat Rev Nephrol, 2016, 12(10): 610-23. doi:10.1038/nrneph.2016.113 |
| [5] | Ghafoury R, Malek M, Ismail-Beigi F, et al. Role of residual inflammation as a risk factor across cardiovascular-kidney-metabolic (CKM) syndrome: unpacking the burden in people with Type2 diabetes[J]. Diabetes Ther, 2025, 16(7): 1341-65. doi:10.1007/s13300-025-01743-6 |
| [6] | Sebastian SA, Padda I, Johal G. Cardiovascular-Kidney-Metabolic (CKM) syndrome: a state-of-the-art review[J]. Curr Probl Cardiol, 2024, 49(2): 102344. doi:10.1016/j.cpcardiol.2023.102344 |
| [7] | Patera F, Gatticchi L, Cellini B, et al. Kidney fibrosis and oxidative stress: from molecular pathways to new pharmacological opportunities[J]. Biomolecules, 2024, 14(1): 137. doi:10.3390/biom14010137 |
| [8] | McPhillips K, Janssen WJ, Ghosh M, et al. TNF-alpha inhibits macrophage clearance of apoptotic cells via cytosolic phospholipase A2 and oxidant-dependent mechanisms[J]. J Immunol, 2007, 178(12): 8117-26. doi:10.4049/jimmunol.178.12.8117 |
| [9] | Zhang CY, Li H, Wang SX. Common gene signatures and molecular mechanisms of diabetic nephropathy and metabolic syndrome[J]. Front Public Health, 2023, 11: 1150122. doi:10.3389/fpubh.2023.1150122 |
| [10] | Salvatore T, Galiero R, Caturano A, et al. An overview of the cardiorenal protective mechanisms of SGLT2 inhibitors[J]. Int J Mol Sci, 2022, 23(7): 3651. doi:10.3390/ijms23073651 |
| [11] | Thomas MC. The clustering of Cardiovascular, Renal, Adipo-Metabolic Eye and Liver disease with type 2 diabetes[J]. Metabolism, 2022, 128: 154961. doi:10.1016/j.metabol.2021.154961 |
| [12] | 张 倩, 徐君瑜, 卢小茜, 等. 中药复杂成分靶点鉴定新方法及其应用研究进展[J]. 中国药理学通报, 2025, 41(11): 2001-8. |
| [13] | 李昇松, 朱明丹. 基于心肾相交 水火既济探讨温阳利水法对慢性心力衰竭的治疗作用[J]. 光明中医, 2025, 40(12): 2533-6. |
| [14] | Ye XQ, Xu YC, Wu SS, et al. Single-cell RNA sequencing reveals the role of immunoinflammatory cells in the progression of renal tubulointerstitial fibrosis[J]. PLoS One, 2025, 20(11): e0337092. doi:10.1371/journal.pone.0337092 |
| [15] | Edgar R. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository[J]. Nucleic Acids Res, 2002, 30(1): 207-10. doi:10.1093/nar/30.1.207 |
| [16] | Ritchie ME, Phipson B, Wu D, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies[J]. Nucleic Acids Res, 2015, 43(7): e47. doi:10.1093/nar/gkv007 |
| [17] | Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis[J]. BMC Bioinform, 2008, 9(1): 559. doi:10.1186/1471-2105-9-559 |
| [18] | Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks[J]. Genome Res, 2003, 13(11): 2498-504. doi:10.1101/gr.1239303 |
| [19] | 国家药典委员会. 中华人民共和国药典-一部: 2020年版[M]. 北京: 中国医药科技出版社, 2020. |
| [20] | Liew A, Bavanandan S, Hao CM, et al. Executive summary of the Asian Pacific society of nephrology clinical practice guideline on diabetic kidney disease-2025 update[J]. Nephrology, 2025, 30(5): e70031. doi:10.1111/nep.70031 |
| [21] | 中华医学会心血管病学分会, 中国医师协会心血管内科医师分会, 中国医师协会心力衰竭专业委员会, 等. 中国心力衰竭诊断和治疗指南2024[J]. 中华心血管病杂志, 2024, 52(3): 235-75. |
| [22] | Handelsman Y. Diabetes, cardiorenal, and metabolic multispecialty practice recommendations and early intensive management of cardio-renal-metabolic disease[J]. Am J Manag Care, 2024, 30(10 ): S189-96. doi:10.37765/ajmc.2024.89671 |
| [23] | Noels H, van der Vorst EPC, Rubin S, et al. Renal-cardiac crosstalk in the pathogenesis and progression of heart failure[J]. Circ Res, 2025, 136(11): 1306-34. doi:10.1161/circresaha.124.325488 |
| [24] | Hou GJ, Dong YZ, Jiang YH, et al. Immune inflammation and metabolic interactions in the pathogenesis of diabetic nephropathy[J]. Front Endocrinol, 2025, 16: 1602594. doi:10.3389/fendo.2025.1602594 |
| [25] | Liu F, Feng QQ, Yang MN, et al. Quercetin prevented diabetic nephropathy by inhibiting renal tubular epithelial cell apoptosis via the PI3K/AKT pathway[J]. Phytother Res, 2024, 38(7): 3594-606. doi:10.1002/ptr.8227 |
| [26] | Wang YY, Liu YY, Li J, et al. Gualou Xiebai decoction ameliorates cardiorenal syndrome type II by regulation of PI3K/AKT/NF-κB signalling pathway[J]. Phytomedicine, 2024, 123: 155172. doi:10.1016/j.phymed.2023.155172 |
| [27] | Williams RO, Clanchy FI, Huang YS, et al. TNFR2 signalling in inflammatory diseases[J]. Best Pract Res Clin Rheumatol, 2024, 38(2): 101941. doi:10.1016/j.berh.2024.101941 |
| [28] | Hubbi S, Hao SJ, Epps J, et al. Tumour necrosis factor-alpha at the intersection of renal epithelial and immune cell function[J]. J Physiol, 2025, 603(10): 2915-36. doi:10.1113/jp286756 |
| [29] | Feng Q, Yu XY, Xie JW, et al. Phillygenin improves diabetic nephropathy by inhibiting inflammation and apoptosis via regulating TLR4/MyD88/NF‑κB and PI3K/AKT/GSK3β signaling pathways[J]. Phytomedicine, 2025, 136: 156314. doi:10.1016/j.phymed.2024.156314 |
| [30] | Delalat S, Sultana I, Osman H, et al. Dysregulated inflammation, oxidative stress, and protein quality control in diabetic HFpEF: unraveling mechanisms and therapeutic targets[J]. Cardiovasc Diabetol, 2025, 24(1): 211. doi:10.1186/s12933-025-02734-4 |
| [31] | Jiang ZW, Tabuchi C, Gayer SG, et al. Immune dysregulation in obesity[J]. Annu Rev Pathol Mech Dis, 2025, 20: 483-509. doi:10.1146/annurev-pathmechdis-051222-015350 |
| [32] | Chen JH, Liu QH, He JH, et al. Immune responses in diabetic nephropathy: Pathogenic mechanisms and therapeutic target[J]. Front Immunol, 2022, 13: 958790. doi:10.3389/fimmu.2022.958790 |
| [33] | Javed Q. Molecular mechanisms and complications of TNF blockade in heart failure: targeting signalling and genetic determinants of therapeutic response[J]. Mol Biol Rep, 2025, 52(1): 772. doi:10.1007/s11033-025-10877-6 |
| [34] | Levine B, Kalman J, Mayer L, et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure[J]. N Engl J Med, 1990, 323(4): 236-41. doi:10.1056/nejm199007263230405 |
| [35] | 张泸丹, 王新陆, 朱明军, 等. 线粒体氧化磷酸化结合中医药在心血管疾病中的研究[J]. 世界科学技术-中医药现代化, 2025, 27(6): 1786-94. |
| [36] | Xiao TH, Zhu BT. Sodium formate-induced mitochondrial impairment and cytotoxicity in neuronal cells reveal crucial pathogenic mechanisms underlying diabetic neuropathy and retinopathy[J]. Sci Rep, 2025, 15: 27797. doi:10.1038/s41598-025-11312-3 |
| [37] | Yang HM. Mitochondrial dysfunction in cardiovascular diseases[J]. Int J Mol Sci, 2025, 26(5): 1917. doi:10.3390/ijms26051917 |
| [38] | Blanda V, Bracale UM, Di Taranto MD, et al. Galectin-3 in cardiovascular diseases[J]. Int J Mol Sci, 2020, 21(23): 9232. doi:10.3390/ijms21239232 |
| [39] | Di Carlo SE, Raffenne J, Varet H, et al. Depletion of slow-cycling PDGFRα+ADAM12+ mesenchymal cells promotes antitumor immunity by restricting macrophage efferocytosis[J]. Nat Immunol, 2023, 24(11): 1867-78. doi:10.1038/s41590-023-01642-7 |
| [40] | Erriah M, Pabreja K, Fricker M, et al. Galectin-3 enhances monocyte-derived macrophage efferocytosis of apoptotic granulocytes in asthma[J]. Respir Res, 2019, 20(1): 1. doi:10.1186/s12931-018-0967-9 |
| [41] | Hussain S, Habib A, Hussain MS, et al. Potential biomarkers for early detection of diabetic kidney disease[J]. Diabetes Res Clin Pract, 2020, 161: 108082. doi:10.1016/j.diabres.2020.108082 |
| [42] | Trippel TD, Mende M, Düngen HD, et al. The diagnostic and prognostic value of galectin-3 in patients at risk for heart failure with preserved ejection fraction: results from the DIAST-CHF study[J]. ESC Heart Fail, 2021, 8(2): 829-41. doi:10.1002/ehf2.13174 |
| [43] | Cheng DM, Lian WX, Jia XY, et al. LGALS3 regulates endothelial-to-mesenchymal transition via PI3K/AKT signaling pathway in silica-induced pulmonary fibrosis[J]. Toxicology, 2024, 509: 153962. doi:10.1016/j.tox.2024.153962 |
| [44] | Song MJ, Pan QZ, Yang JY, et al. Galectin-3 favours tumour metastasis via the activation of β-catenin signalling in hepatocellular carcinoma[J]. Br J Cancer, 2020, 123(10): 1521-34. doi:10.1038/s41416-020-1022-4 |
| [45] | Dong R, Zhang M, Hu QY, et al. Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review)[J]. Int J Mol Med, 2018, 41(2): 599-614. |
| [46] | Ianos RD, Iancu M, Pop C, et al. Predictive value of NT-proBNP, FGF21, galectin-3 and copeptin in advanced heart failure in patients with preserved and mildly reduced ejection fraction and type 2 diabetes mellitus[J]. Medicina, 2024, 60(11): 1841. doi:10.3390/medicina60111841 |
| [47] | Medvedeva EA, Berezin II, Shchukin YV. Galectin-3, Markers of Oxidative Stress and Renal Dysfunction in Patients With Chronic Heart Failure[J]. Kardiologiia, 2017, 57(3): 46-50. |
| [48] | 朴容硕, 王 薇, 李应东, 等. 6种益气活血类中成药治疗慢性心力衰竭的网状Meta分析[J]. 中国中药杂志, 2022, 47(15): 4221-37. doi:10.19540/j.cnki.cjcmm.20220510.502 |
| [49] | Lu Q, Ji XJ, Zhou YX, et al. Quercetin inhibits the mTORC1/p70S6K signaling-mediated renal tubular epithelial–mesenchymal transition and renal fibrosis in diabetic nephropathy[J]. Pharmacol Res, 2015, 99: 237-47. doi:10.1016/j.phrs.2015.06.006 |
| [50] | Li ZY, Deng HC, Guo XC, et al. Effective dose/duration of natural flavonoid quercetin for treatment of diabetic nephropathy: a systematic review and meta-analysis of rodent data[J]. Phytomedicine, 2022, 105: 154348. doi:10.1016/j.phymed.2022.154348 |
| [51] | Lei L, Zhao J, Liu XQ, et al. Wogonin alleviates kidney tubular epithelial injury in diabetic nephropathy by inhibiting PI3K/Akt/NF-κB signaling pathways[J]. Drug Des Devel Ther, 2021, 15: 3131-50. doi:10.2147/dddt.s310882 |
| [52] | Liu XQ, Jiang L, Li YY, et al. Wogonin protects glomerular podocytes by targeting Bcl-2-mediated autophagy and apoptosis in diabetic kidney disease[J]. Acta Pharmacol Sin, 2022, 43(1): 96-110. doi:10.1038/s41401-021-00721-5 |
| [53] | Zhao FL, Fu L, Yang W, et al. Cardioprotective effects of baicalein on heart failure via modulation of Ca2+ handling proteins in vivo and in vitro [J]. Life Sci, 2016, 145: 213-23. doi:10.1016/j.lfs.2015.12.036 |
| [54] | Ahad A, Mujeeb M, Ahsan H, et al. Prophylactic effect of baicalein against renal dysfunction in type 2 diabetic rats[J]. Biochimie, 2014, 106: 101-10. doi:10.1016/j.biochi.2014.08.006 |
| [55] | Sun LW, Isaak CK, Zhou YL, et al. Salidroside and tyrosol from Rhodiola protect H9c2 cells from ischemia/reperfusion-induced apoptosis[J]. Life Sci, 2012, 91(5/6): 151-8. doi:10.1016/j.lfs.2012.06.026 |
| [56] | Tian CX, Li MY, Shuai XX, et al. Berberine plays a cardioprotective role by inhibiting macrophage Wnt5a/β‑catenin pathway in the myocardium of mice after myocardial infarction[J]. Phytother Res, 2023, 37(1): 50-61. doi:10.1002/ptr.7592 |
| [57] | Zhao M, Li PY, Qiao D, et al. N6-methyladenosine modification of TSC1 mRNA contributes to macrophage polarization regulated by Coptisine in DSS-induced ulcerative colitis[J]. Phytomedicine, 2024, 122: 155153. doi:10.1016/j.phymed.2023.155153 |
| [58] | 田 蕾, 赵文景, 刘伟敬, 等. 糖尿病肾脏疾病“肾络微型癥瘕聚散消长”理论体系的构建与应用[J]. 中华中医药杂志, 2025, 40(7): 3423-6. |
| [59] | 高亚斌, 王耀献, 郭 敬, 等. “以热为本, 以期为纲”论治晚期糖尿病肾病[J]. 中华中医药杂志, 2020, 35(2): 714-6. |
| [60] | 刘晓芹, 王 雯, 程丽霞. 中医药治疗糖尿病肾脏病的现状及研究进展[J]. 中医药导报, 2024, 30(6): 152-5. |
| [1] | Ai QIAN, Chuanbing HUANG, Yawen ZHU, Kexin HU, Xinran SONG, Yuxiang XU. Qihuang Jianpi Zishen Granule ameliorates renal injury in patients with systemic lupus erythematosus by regulating immunometabolic reprogramming of macrophages [J]. Journal of Southern Medical University, 2026, 46(9): 2113-2122. |
| [2] | Yuanyuan MA, Yue LIU, Ning GAO, Yumeng HUO, Meini CHEN, Jiawen LI, Jiahao LIU, Manqiu ZHANG, Bingbing YAN, Nuo XU, Jumei ZHAO. Multiple components in Astragalus Injection target CCL2/FOS/PPARG/CXCL8 to suppress cervical cancer progression [J]. Journal of Southern Medical University, 2026, 46(9): 2206-2221. |
| [3] | Zaoqiang LIN, Mengyao JIANG, Liuchang FENG, Kunyang FANG, Pingjun FANG, Qinxiang TAN. Rehmanniae radix preparata alleviates chronic kidney disease in mice through a multi-target mechanism [J]. Journal of Southern Medical University, 2026, 46(7): 1611-1621. |
| [4] | Yuanyuan CHENG, Chuanbing HUANG, Juan ZHANG, Yawen ZHU, Ai QIAN. Chonggu Granules attenuate cartilage injury in knee osteoarthritis patients with liver-kidney deficiency syndrome by regulating the Nrf2 pathway [J]. Journal of Southern Medical University, 2026, 46(5): 1028-1038. |
| [5] | Liang HAN, Baichao LI, Bingzhe WANG, Zhiwei ZHANG, Jiuna ZHANG. Cephaeline attenuates malignant biological behaviors of colorectal cancer by regulating the Ras signaling pathway [J]. Journal of Southern Medical University, 2026, 46(5): 1121-1130. |
| [6] | Jiarun XIE, Yanyu LUO, Jinjin XIA, Ming WANG. Jia Wei Qingxin Lotus Seed Drink improves diabetic kidney disease in mice by regulating the KDM3C/SP1 signaling pathway [J]. Journal of Southern Medical University, 2026, 46(4): 728-741. |
| [7] | Yang MA, Longhui GUO, Jinguo WANG, Wenpin XIAO, Yuncheng LV, Xiaoming FAN. Scutellarin improves metabolic dysfunction-associated steatotic liver disease in rats by regulating MMP7 and LCN2 [J]. Journal of Southern Medical University, 2026, 46(4): 907-922. |
| [8] | Xuejun CHEN, Yuan JING, Huiyu LIANG, Jingying ZHONG, Zedong CHEN, Yuzhi PENG, Jiaojiao DAI, Ya XIAO. Different Astragalus medicinal pairs improve diabetic nephropathy in mice by regulating lipid peroxidation through PTGS2 [J]. Journal of Southern Medical University, 2026, 46(3): 592-603. |
| [9] | Zhaoyong LI, Fenghua ZHOU, Xiaomin SUN, Huashan ZHAO, Yao JIN, Peikun HE, Yuhua JIA. Jiangzhi Quban Recipe improves type 2 diabetes mellitus complicated with hyperlipidemia by multi-target regulation of the inflammation-metabolism network: network pharmacology analysis and clinical validation [J]. Journal of Southern Medical University, 2026, 46(1): 83-93. |
| [10] | Qin HU, Hua JIN. Qingshen Granules improves renal function of patients with chronic kidney disease damp-heat syndrome by activating the miR-23b and Nrf2 pathway [J]. Journal of Southern Medical University, 2025, 45(9): 1867-1879. |
| [11] | Ziwei YANG, Chang LÜ, Zhu DONG, Shulei JI, Shenghui BI, Xuehua ZHANG, Xiaowu WANG. Rosa laevigata Michx. inhibits pulmonary arterial smooth muscle cell proliferation in hypertension by modulating the Src-AKT1 axis [J]. Journal of Southern Medical University, 2025, 45(9): 1889-1902. |
| [12] | Qianqian MA, Yuqi NIU, Mingyu ZUO, Xin LI, Junke FU, Jinjin WANG. Guijianyu alleviates advanced glycation endproducts-induced mouse renal podocyte injury by inhibiting the AGEs-RAGE signaling pathway [J]. Journal of Southern Medical University, 2025, 45(9): 1938-1945. |
| [13] | Qi YUN, Ruoli DU, Yuying HE, Yixin ZHANG, Jiahui WANG, Hongwei YE, Zhenghong LI, Qin GAO. Cinnamic acid ameliorates doxorubicin-induced myocardial injury in mice by attenuating cardiomyocyte ferroptosis via inhibiting TLR4 [J]. Journal of Southern Medical University, 2025, 45(9): 1946-1958. |
| [14] | Lu RAO, Jiahe DING, Jiangping WEI, Yong YANG, Xiaomei ZHANG, Jirui WANG. Flos Sophorae improves psoriasis in mice by inhibiting the PI3K/AKT pathway [J]. Journal of Southern Medical University, 2025, 45(9): 1989-1996. |
| [15] | Xinyuan CHEN, Chengting WU, Ruidi LI, Xueqin PAN, Yaodan ZHANG, Junyu TAO, Caizhi LIN. Shuangshu Decoction inhibits growth of gastric cancer cell xenografts by promoting cell ferroptosis via the P53/SLC7A11/GPX4 axis [J]. Journal of Southern Medical University, 2025, 45(7): 1363-1371. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||